Jefferies raised estimates and its price target on Buy-rated Biogen (NASDAQ: BIIB) from $215 to $248 following Q1 results.

This article: 122 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE